|
1
|
Spahr L, Giostra E, Frossard JL, Morard I,
Mentha G and Hadengue A: A 3-month course of long-acting repeatable
octreotide (sandostatin LAR) improves portal hypertension
inpatients with cirrhosis: A randomized controlled study. Am J
Gastroenterol. 102:1397–1405. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Biron E, Chatterjee J, Ovadia O,
Langenegger D, Brueggen J, Hoyer D, Schmid HA, Jelinek R, Gilon C,
Hoffman A and Kessler H: Improving oral bioavailability of peptides
by multiple N-methylation: Somatostatin analogues. Angew Chem Int
Ed Engl. 47:2595–2599. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maggio ET and Grasso P: Oral delivery of
octreotide acetate in Intravail® improves uptake,
half-life, and bioavailability over subcutaneous administration in
male Swiss Webster mice. Regul Pept. 167:233–238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li YL, Duan ZJ, Tian Y, Liu Z and Wang QM:
A novel perspective and approach to intestinal octreotide
absorption: Sinomenine-mediated reversible tight junction opening
and its molecular mechanism. Int J Mol Sci. 14:12873–12892. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thanou M, Verhoef JC, Marbach P and
Junginger HE: Intestinal absorption of octreotide: N-trimethyl
chitosan chloride (TMC) ameliorates the permeability and absorption
properties of the somatostatin analogue in vitro and in vivo. J
Pharm Sci. 89:951–957. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tuvia S, Atsmon J, Teichman SL, Katz S,
Salama P, Pelled D, Landau I, Karmeli I, Bidlingmaier M,
Strasburger CJ, et al: Oral octreotide absorption in human
subjects: Comparable pharmacokinetics to parenteral octreotide and
effective growth hormone suppression. J Clin Endocrinol Metab.
97:2362–2369. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McDevitt CA and Callaghan R: How can we
best use structural information on P-glycoprotein to design
inhibitors? Pharmacol Ther. 113:429–441. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gomes P, Vale N and Moreira R:
Cyclization-activated prodrugs. Molecules. 12:2484–2506. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Drewe J, Fricker G, Vonderscher J and
Beglinger C: Enteral absorption of octreotide: Absorption
enhancement by polyoxyethylene-24-cholesterol ether. Br J
Pharmacol. 108:298–303. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ghosh RD, Chakraborty P, Banerjee K,
Adhikary A, Sarkar A, Chatterjee M, Das T and Choudhuri SK: The
molecular interaction of a copper chelate with human
P-glycoprotein. Mol Cell Biochem. 364:309–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gu L, Chen J, Synold TW, Forman BM and
Kane SE: Bioimaging real-time PXR-dependent mdr1a gene regulation
in mdr1a.fLUC reporter mice. J Pharmacol Exp Ther. 345:438–445.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo SB, Duan ZJ, Li Q and Sun XY: Effect
of heme oxygenase-1 on renal function in rats with liver cirrhosis.
World J Gastroenterol. 17:322–328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thanou M, Verhoef JC, Verheijden JH and
Junginger HE: Intestinal absorption of octreotide using trimethyl
chitosan chloride: Studies in pigs. Pharm Res. 18:823–828. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miao Q, Liu Q, Wang C, Meng Q, Guo X, Peng
J, Kaku T and Liu K: Inhibitory effect of zinc on the absorption of
JBP485 via the gastrointestinal oligopeptide transporter (PEPT1) in
rats. Drug Metab Pharmacokinet. 26:494–502. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
|
|
16
|
Gutmann H, Miller DS, Droulle A, Drewe J,
Fahr A and Fricker G: P-glycoprotein- and mrp2-mediated octreotide
transport in renal proximal tubule. Br J Pharmacol. 129:251–256.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fricker G, Nobmann S and Miller DS:
Permeability of porcine blood brain barrier to somatostatin
analogues. Br J Pharmacol. 135:1308–1314. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fang HM, Xu JM, Mei Q, Diao L, Chen ML,
Jin J and Xu XH: Involvement of cytochrome P450 3A4 and
P-glycoprotein in first-pass intestinal extraction of omeprazole in
rabbits. Acta pharmacol Sin. 30:1566–1572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zollner G, Fickert P, Zenz R, Fuchsbichler
A, Stumptner C, Kenner L, Ferenci P, Stauber RE, Krejs GJ, Denk H,
et al: Hepatobiliary transporter expression in percutaneous liver
biopsies of patients with cholestatic liver diseases. Hepatology.
33:633–646. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kneuer C, Honscha W, Gäbel G and Honscha
KU: Adaptive response to increased bile acids: Induction of MDR1
gene expression and P-glycoprotein activity in renal epithelial
cells. Pflugers Arch. 454:587–594. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang H, Liao ZX, Chen M and Hu XL: Effects
of hepatic fibrosis on ofloxacin pharmacokinetics. Pharmacol Res.
53:28–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zollner G, Fickert P, Silbert D,
Fuchsbichler A, Marschall HU, Zatloukal K, Denk H and Trauner M:
Adaptive changes in hepatobiliary transporter expression in primary
biliary cirrhosis. J Hepatol. 38:717–727. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barnes SN, Aleksunes LM, Augustine L,
Scheffer GL, Goedken MJ, Jakowski AB, Pruimboom-Brees IM,
Cherrington NJ and Manautou JE: Induction of hepatobiliary efflux
transporters in acetaminophen-induced acute liver failure cases.
Drug Metab Dispos. 35:1963–1969. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cho YA, Lee W and Choi JS: Effects of
curcumin on the pharmacokinetics of tamoxifen and its active
metabolite, 4-hydroxytamoxifen, in rats: Possible role of CYP3A4
and P-glycoprotein inhibition by curcumin. Pharmazie. 67:124–130.
2012.PubMed/NCBI
|
|
25
|
Scaglione F: New oral anticoagulants:
Comparative pharmacology with vitamin K antagonists. Clin
Pharmacokinet. 52:69–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fricker G, Fahr A, Beglinger C, Kissel T,
Reiter G and Drewe J: Permeation enhancement of octreotide by
specific bile salts in rats and human subjects: In vitro, in vivo
correlations. Br J Pharmacol. 117:217–223. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kullak-Ublick GA, Baretton GB, Oswald M,
Renner EL, Paumgartner G and Beuers U: Expression of the hepatocyte
canalicular multidrug resistance protein (MRP2) in primary biliary
cirrhosis. Hepatol Res. 23:78–82. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eldesoky ES, Kamel SI, Farghaly AM,
Bakheet MY, Hedaya MA and Siest JP: Study of the urinary ratio of 6
beta-hydroxycortisol/cortisol as a biomarker of CYP3A4 activity in
Egyptian patients with chronic liver diseases. Biomarker Insights.
1:157–164. 2007.PubMed/NCBI
|
|
29
|
Orlando R, Piccoli P, De Martin S, Padrini
R and Palatini P: Effect of the CYP3A4 inhibitor erythromycin on
the pharmacokinetics of lignocaine and its pharmacologically active
metabolites in subjects with normal and impaired liver function. Br
J Clin Pharmacol. 55:86–93. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aihua L, Ping L, Fenghua LI, Yongping MU,
Guangli DU and Lei W: Dynamic changes of cholestatic cirrhosis in
rats and its significance. Chin J Integr Tradit Western Nephrol.
16:87–89. 2006.
|
|
31
|
Medina-Díaz IM, Estrada-Muñiz E,
Reyes-Hernández OD, Ramírez P, Vega L and Elizondo G: Arsenite and
its metabolites, MMA (III) and DMA (III), modify CYP3A4, PXR and
RXR alpha expression in the small intestine of CYP3A4 transgenic
mice. Toxicol Appl Pharmacol. 239:162–168. 2009. View Article : Google Scholar : PubMed/NCBI
|
